STAT

Opinion: Bringing transparency to the notion of price transparency

Transparency is not just a goal. It's also an ethic. Organizations involved in price transparency initiatives should be transparent in the ways appropriate to them.
President Trump signs an executive order on health care price transparency at the White House in June.

Health care price transparency is making headlines again. In late July, in accord with a recent presidential executive order, the Centers for Medicare and Medicaid Services issued a proposed rule requiring hospitals to make more price information publicly available.

The growing interest in price transparency isn’t limited to one side of the aisle or one branch of government. Republican and Democratic members of various committees in both the House and the Senate have introduced bills to advance price transparency, each with its critics and proponents. Nor are the calls for transparency all coming from the top down. Private groups representing different perspectives in the health care system, including hospitals, medical societies, insurers,

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.

Related Books & Audiobooks